JP2019521103A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521103A5
JP2019521103A5 JP2018563792A JP2018563792A JP2019521103A5 JP 2019521103 A5 JP2019521103 A5 JP 2019521103A5 JP 2018563792 A JP2018563792 A JP 2018563792A JP 2018563792 A JP2018563792 A JP 2018563792A JP 2019521103 A5 JP2019521103 A5 JP 2019521103A5
Authority
JP
Japan
Prior art keywords
binding molecule
cd32b
cd79b
dose
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521103A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/036079 external-priority patent/WO2017214096A1/en
Publication of JP2019521103A publication Critical patent/JP2019521103A/ja
Publication of JP2019521103A5 publication Critical patent/JP2019521103A5/ja
Priority to JP2022093028A priority Critical patent/JP2022120061A/ja
Priority to JP2024071096A priority patent/JP2024102146A/ja
Pending legal-status Critical Current

Links

JP2018563792A 2016-06-07 2017-06-06 炎症性疾患及び障害の治療におけるcd32b×cd79b結合分子の使用方法 Pending JP2019521103A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022093028A JP2022120061A (ja) 2016-06-07 2022-06-08 炎症性疾患及び障害の治療におけるcd32b×cd79b結合分子
JP2024071096A JP2024102146A (ja) 2016-06-07 2024-04-25 炎症性疾患及び障害の治療におけるcd32b×cd79b結合分子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346717P 2016-06-07 2016-06-07
US62/346,717 2016-06-07
US201662432328P 2016-12-09 2016-12-09
US62/432,328 2016-12-09
PCT/US2017/036079 WO2017214096A1 (en) 2016-06-07 2017-06-06 Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022093028A Division JP2022120061A (ja) 2016-06-07 2022-06-08 炎症性疾患及び障害の治療におけるcd32b×cd79b結合分子
JP2024071096A Division JP2024102146A (ja) 2016-06-07 2024-04-25 炎症性疾患及び障害の治療におけるcd32b×cd79b結合分子

Publications (2)

Publication Number Publication Date
JP2019521103A JP2019521103A (ja) 2019-07-25
JP2019521103A5 true JP2019521103A5 (cg-RX-API-DMAC10.html) 2020-06-18

Family

ID=60578080

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018563792A Pending JP2019521103A (ja) 2016-06-07 2017-06-06 炎症性疾患及び障害の治療におけるcd32b×cd79b結合分子の使用方法
JP2022093028A Pending JP2022120061A (ja) 2016-06-07 2022-06-08 炎症性疾患及び障害の治療におけるcd32b×cd79b結合分子
JP2024071096A Pending JP2024102146A (ja) 2016-06-07 2024-04-25 炎症性疾患及び障害の治療におけるcd32b×cd79b結合分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022093028A Pending JP2022120061A (ja) 2016-06-07 2022-06-08 炎症性疾患及び障害の治療におけるcd32b×cd79b結合分子
JP2024071096A Pending JP2024102146A (ja) 2016-06-07 2024-04-25 炎症性疾患及び障害の治療におけるcd32b×cd79b結合分子

Country Status (11)

Country Link
US (1) US20190322741A1 (cg-RX-API-DMAC10.html)
EP (1) EP3464378A4 (cg-RX-API-DMAC10.html)
JP (3) JP2019521103A (cg-RX-API-DMAC10.html)
KR (3) KR20250021614A (cg-RX-API-DMAC10.html)
CN (1) CN109311990A (cg-RX-API-DMAC10.html)
AU (1) AU2017278329B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018075303A2 (cg-RX-API-DMAC10.html)
MX (2) MX2018015265A (cg-RX-API-DMAC10.html)
RU (1) RU2022101891A (cg-RX-API-DMAC10.html)
TW (1) TW201742633A (cg-RX-API-DMAC10.html)
WO (1) WO2017214096A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
JP2022513338A (ja) * 2018-10-03 2022-02-07 ネペンザ・バイオサイエンシズ・エルエルシー 抗cd79抗体およびその使用
CN114502587A (zh) * 2019-07-30 2022-05-13 普瑞文森生物有限公司 通过非耗竭性b细胞抑制剂降低免疫原性的方法和组合物
KR20220091458A (ko) * 2019-07-30 2022-06-30 프로벤션 바이오, 인코포레이티드 비-고갈성 b 세포 억제제에 의한 면역원성을 감소시키기 위한 방법 및 조성물
WO2021207681A1 (en) * 2020-04-10 2021-10-14 The Board Of Trustees Of The Leland Stanford Junior University Targeted reduction of activated immune cells
KR20230113312A (ko) * 2020-11-01 2023-07-28 프로벤션 바이오, 인코포레이티드 루푸스 치료 방법 및 조성물
CA3231174A1 (en) * 2021-08-02 2023-02-09 Innovent Biologics (Suzhou) Co., Ltd. Anti-cd79bxcd3 bispecific antibody and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11384149B2 (en) * 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
AU2016207758C1 (en) * 2015-01-13 2020-05-28 New Zealand Institute For Bioeconomy Science Limited Agricultural composition

Similar Documents

Publication Publication Date Title
RU2022101891A (ru) Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств
JP2021522801A5 (cg-RX-API-DMAC10.html)
JP2019511212A5 (cg-RX-API-DMAC10.html)
JP2017522043A5 (cg-RX-API-DMAC10.html)
JP2020525032A5 (cg-RX-API-DMAC10.html)
US20200069797A1 (en) Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
Perosa et al. CD20: a target antigen for immunotherapy of autoimmune diseases
JP2018509413A5 (cg-RX-API-DMAC10.html)
JP2018512138A5 (cg-RX-API-DMAC10.html)
JP2016507555A5 (cg-RX-API-DMAC10.html)
CA3120096A1 (en) Cd25 antibodies
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP6731403B2 (ja) 免疫応答およびがん治療の増強に使用するための組成物および方法
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
JP2018501813A5 (cg-RX-API-DMAC10.html)
JP2023113636A5 (cg-RX-API-DMAC10.html)
JP2020513791A5 (cg-RX-API-DMAC10.html)
JP2018527919A5 (cg-RX-API-DMAC10.html)
JP2020500542A5 (cg-RX-API-DMAC10.html)
JP2019502676A5 (cg-RX-API-DMAC10.html)
JP2016527314A5 (cg-RX-API-DMAC10.html)
JP2017113004A5 (cg-RX-API-DMAC10.html)
JP2016508153A5 (cg-RX-API-DMAC10.html)
JP2016527187A5 (cg-RX-API-DMAC10.html)
JP2023505492A5 (cg-RX-API-DMAC10.html)